Biohaven委任John Yetimoglu為董事 獲授逾71萬美元購股權

bhvn-202608030001935979false00019359792026-08-032026-08-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of 
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2026
Biohaven Ltd.
(Exact name of registrant as specified in its charter)

British Virgin Islands001-41477Not applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(Address of principal executive offices, including zip code)
(203) 404-0410
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a director, effective August 6, 2026. Mr. Yetimoglu will serve in the class of directors whose term will expire at the Company’s 2027 Annual Meeting of Shareholders. Mr. Yetimoglu has also been appointed as a member of the Nominating and Governance Committee of the Board. 

There is no arrangement or understanding between Mr. Yetimoglu and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Yetimoglu and any of the Company’s other directors or executive officers. Since the beginning of the Company’s last fiscal year, there are no transactions in which the Company was or is to be a participant and in which Mr. Yetimoglu or any member of his immediate family had or will have any interest that are required to be reported under Item 404(a) of Regulation S-K.

In accordance with the Company’s compensation policy for non-employee directors, Mr. Yetimoglu is entitled to options to purchase the Company’s common shares with an aggregate grant date fair value of $713,875. The shares underlying these options will vest 25% on grant and 25% on each of the following three anniversaries of grant, subject to Mr. Yetimoglu’s continuous service through each vesting date. Additionally, Mr. Yetimoglu will be entitled to receive a $57,000 annual retainer for his service as a director and committee member.

2

Item 9.01    Financial Statements and Exhibits. 

(d) Exhibits 

Exhibit NumberExhibit Description

104The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

3

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2026

Biohaven Ltd.

By:/s/ Matthew Buten
Matthew Buten
Chief Financial Officer

4